Asia-Pacific Schizophrenia Drugs Market Size & Growth Analysis Report, 2019-2025
Asia-Pacific schizophrenia drugs market is projected to grow at a significant CAGR of 3.6% during the forecast period (2020-2026). In Asia-Pacific, the schizophrenia has a high prevalence in South Asian countries as compared to the rest of the region. According to the Progress in Mind, there are significantly different medication patterns preferred across South Asian countries.
·
42% of patients were prescribed more than 1
antipsychotic; however, polypharmacy rates ranged from 59% in Vietnam to 22% in
Myanmar.
·
Anxiolytics (Pakistan 56% compared to Myanmar 9%)
·
Hypnotics (Japan 61% compared to Sri Lanka and
Myanmar 0%)
·
Anti-Parkinsonian drugs (Bangladesh 88% compared to
Vietnam 11%)
To Request a Sample of our Report on Asia-Pacific Schizophrenia Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-schizophrenia-drugs-market
The presence of
huge population and gender inequality in the South Asian economies, such as
Pakistan and India, has been the major factor for the rising demand for
schizophrenia drugs in these economies. Along with this, the increasing
awareness about mental health in the emerging South Asian economies, such as
India and Vietnam, the schizophrenia drug industry is continuously increasing
and driving the Asia-Pacific schizophrenia drug market. There are several
mental health organizations and hospitals being established in the last decade
and the trend is expected to continue during the forecast period.
(Get 15% Discount on Buying this Report)
A full
Report of Asia-Pacific Schizophrenia Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-schizophrenia-drugs-market
Key questions addressed by the report
·
What is the market growth rate during the forecast
period?
·
Which segment/region dominates the market in the
base year?
·
Which segment/region will project the fastest
growth in the market during the forecast period?
·
How COVID-19 will impact the market growth in 2020
and coming years?
·
Recovery Timeline
·
Deviation from pre-COVID-19
·
Most affected region/segment
·
Recommendations
·
Who is the leader in the market?
·
How players are addressing challenges to sustain
growth?
·
Where is the investment opportunity?
Asia-Pacific Schizophrenia Drugs Market – Segmentation
By Therapeutic Class
·
Second Generation Antipsychotics
·
Third Generation Antipsychotics
·
Others (First Generation Antipsychotics)
By Treatment
·
Oral
·
Injectables
Asia-Pacific Schizophrenia Drugs Market –
Segmentation by Geography
·
China
·
Japan
·
India
Rest of Asia-Pacific
Company Profiles
·
Alkermes PLC
·
Allergan PLC
·
AstraZeneca PLC
·
Biogen Inc.
·
Eli Lilly and Co.
·
H. Lundbeck A/S
·
Johnson & Johnson Services, Inc.
·
Lupin Ltd.
·
Merck & Co., Inc.
·
Otsuka Pharmaceutical Co., Ltd.
·
Pfizer Inc.
·
Teva Pharmaceutical Industries Ltd.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-schizophrenia-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
Media Contact:
Company Name: Orion
Market Research
Contact Person: Mr.
Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment